Scholarlink

<p>Allogeneic hematopoietic cell transplantation (HCT) is a potential cure for patients with peripheral T-/NK-cell lymphomas (PTCL), but its application is understudied. This prospective trial evaluates a unique reduced-intensity (RIC) transplantation platform in 31 patients with PTCL (NCT03922724). One-year progression-free survival, the primary endpoint, is 53% (95% CI 29-72%) on the RIC arm and 60% (95% CI 25-83%) on the modified-RIC arm. The 3-year overall survival is 61% (95% CI 42-76%), with relapse estimated at 18% (95% CI 6-34%) at 3 years. Transplant-related mortality was 24% (95% CI 10-41%) at 1-year, low at 11% (95% CI 2-29%) for patients ≤60 years but 56% (95% CI 17-82%) for patients &gt;60 years, <i>p</i> = 0.01. There was no grade III-IV acute graft-versus-host disease, while chronic graft-versus-host disease was estimated at 23% (95 CI 10-38%) at 2 years. This study demonstrates a benefit regardless of pre-transplantation disease status, challenging the requirement of remission for HCT.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Allogeneic hematopoietic cell transplantation in mature T- or NK-lymphomas: a phase II clinical trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月23日

查看全文
  • Kamil A. Rechache,
  • Natalia S. Nunes,
  • Jennifer Sponaugle,
  • Elisabetta Xue,
  • Amy Chai,
  • Rebecca Combs,
  • Jessenia Campos,
  • Xingmin Feng,
  • Francis A. Flomerfelt,
  • Kalpana Upadhyaya,
  • William Telford,
  • Brian Dawson,
  • Thomas E. Hughes,
  • Syed Muhammad Salman Shah,
  • Alicia Peluso,
  • Christi McKeown,
  • Anita Stokes,
  • Scott Napier,
  • Ruby Sabina,
  • Jennifer Wilder,
  • Kristen Cole,
  • Judy Baruffaldi,
  • Jennifer Cuellar-Rodriguez,
  • Juan Gea-Banacloche,
  • Mary M. Czech,
  • Mustafa A. Hyder,
  • Christopher G. Kanakry,
  • Dimana Dimitrova,
  • Jennifer A. Kanakry

摘要

Allogeneic hematopoietic cell transplantation (HCT) is a potential cure for patients with peripheral T-/NK-cell lymphomas (PTCL), but its application is understudied. This prospective trial evaluates a unique reduced-intensity (RIC) transplantation platform in 31 patients with PTCL (NCT03922724). One-year progression-free survival, the primary endpoint, is 53% (95% CI 29-72%) on the RIC arm and 60% (95% CI 25-83%) on the modified-RIC arm. The 3-year overall survival is 61% (95% CI 42-76%), with relapse estimated at 18% (95% CI 6-34%) at 3 years. Transplant-related mortality was 24% (95% CI 10-41%) at 1-year, low at 11% (95% CI 2-29%) for patients ≤60 years but 56% (95% CI 17-82%) for patients >60 years, p = 0.01. There was no grade III-IV acute graft-versus-host disease, while chronic graft-versus-host disease was estimated at 23% (95 CI 10-38%) at 2 years. This study demonstrates a benefit regardless of pre-transplantation disease status, challenging the requirement of remission for HCT.